In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $3.28.
According to TipRanks, LeBoyer is a 2-star analyst with an average return of 0.0% and a 25.17% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Ayala Pharmaceuticals, Axcella Health, and Onconova Therapeutics.
Currently, the analyst consensus on PDS Biotechnology is a Strong Buy with an average price target of $12.50, representing a 281.10% upside. In a report released on September 21, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
PDSB market cap is currently $93.34M and has a P/E ratio of -3.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PDS Biotech to Participate at Cantor Fitzgerald’s Oncology & HemOnc Conference
- PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
- PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
- PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
